# Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Study · id `cardio:ct-nct04916470` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04916470](<https://clinicaltrials.gov/study/NCT04916470>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04916470

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 617 participants.

## Technical summary

Registry record NCT04916470. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-15 (actual); primary completion 2023-10-11 (actual). Results posted on 2026-11-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 617 participants (enrolled count; ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Started: 2021-06-15 (actual) (ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Primary completion: 2023-10-11 (actual) (ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Completion: 2023-10-11 (actual) (ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Results first posted: 2026-11-02 (ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Countries: United States; Argentina; Austria; Canada; Czechia; Germany; Hungary; India; Israel; Italy; Japan; Netherlands; Poland; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT04916470, source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04916470-2026-11-02`, retrieved 2026-11-18)

## The registry's words

- Brief title: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
- Acronym: STEP HFpEF DM
- Condition: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo (Semaglutide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (`cardio:pubmed-38587233`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial (`cardio:pubmed-39848268`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: cc9990d048dd38929da2e29618f42dc14f49c46eb76475abb81ed97713893232
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
